Effects of antiretroviral drug combinations on the differentiation of adipocytes
- 1 January 2002
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 16 (1) , 13-20
- https://doi.org/10.1097/00002030-200201040-00003
Abstract
Preadipocyte cell lines present a cell model with which to understand the physiopathological mechanisms underlying lipodystrophy syndrome, a common complication observed in patients treated with highly active antiretroviral therapy (HAART) that, in general, is associated with the use of protease inhibitors (PI) and nucleoside reverse transcriptase inhibitors (NRTI). The aim of this study was to evaluate the effects of NRTI and of PI and NRTI combinations in this cell model. The differentiation of 3T3-F442A cells was studied by monitoring the expression of specific genes in the presence of therapeutic concentrations of antiretroviral drugs. Messenger RNA (mRNA) was quantified by two reverse transcription–PCR-based methods. In the presence of 2 μM saquinavir, 30 μM ritonavir or 1 μM zidovudine preadipocytes delayed their differentiation, whereas the use of 10 μM nelfinavir led to cell death. Indinavir (10 μM) promoted lipoprotein lipase expression whereas 1 μM lamivudine or 1μM stavudine enhanced slightly the expression of the malic enzyme gene. However, the combination of indinavir, lamivudine and stavudine led to a large increase in both lipoprotein lipase and malic enzyme mRNA transcription whereas the combination of indinavir, lamivudine and zidovudine led to a 2.5-fold increase in the expression of the lipogenic malic enzyme gene. Similar potentiating effects of NRTI and PI were observed on the expression of the fatty acid synthase gene. Our data suggest that, like PI (although to a lesser extent) NRTI interfere with the differentiation process of adipocytes. In addition, we demonstrate that the effects produced by combinations of NRTI and PI are different from those elicited by each drug separately. This point may be particularly relevant in understanding the physiopathological mechanisms underlying the lipodystrophic syndrome.Keywords
This publication has 47 references indexed in Scilit:
- HIV-1 protease inhibitor–associated partial lipodystrophy: Clinicopathologic review of 14 cases☆, ☆☆Journal of the American Academy of Dermatology, 2000
- Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease InhibitorsCirculation, 1999
- Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patientsAIDS, 1998
- Development of Cervical Fat Pads Following Therapy with Human Immunodeficiency Virus Type 1 Protease InhibitorsClinical Infectious Diseases, 1998
- “Buffalo hump” in HIV-1 infectionThe Lancet, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Visceral abdominal-fat accumulation associated with use of indinavirThe Lancet, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997